AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29179601 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study 28750695 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor 60 mg twice daily + low-dose aspirin (ASA)
Number of subjects: 21162
Study 28750695 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor 60 mg twice daily + low-dose ASA
Number of subjects: 21162
Study 28750695 — intervention group
Group type: COMPARATOR
Intervention: Placebo + low-dose aspirin (ASA)
Number of subjects: 21162
Study 25968470 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training (A)
Number of subjects: 44
Study 25968470 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance strength training (B)
Number of subjects: 44
Study 22645405 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Palliative advanced homecare and heart Failure care (PREFER)
Number of subjects: 0
Study 22645405 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 21597401 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic peritoneal fenestration
Number of subjects: 130
Study 21597401 — intervention group
Group type: COMPARATOR
Intervention: Standard surgical procedure without fenestration
Number of subjects: 130
Study 19406232 — intervention group
Group type: EXPERIMENTAL
Intervention: Lyophilized orally disintegrating tablets (ODTs) of nimesulide (100mg)
Number of subjects: 0
Study 19406232 — intervention group
Group type: COMPARATOR
Intervention: Conventional immediate release tablet (Sulide)
Number of subjects: 0
Study 17003295 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 1513
Study 17003295 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1513
Study 15302082 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation
Number of subjects: 18
Study 15302082 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 11134193 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin (n = 637, median total dose of 294 mg/m(2))
Number of subjects: 1000
Study 11134193 — intervention group
Group type: COMPARATOR
Intervention: CMF regimen (n = 363)
Number of subjects: 1000
Study 11134193 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin-treated patients
Number of subjects: 1000
Study 11134193 — intervention group
Group type: COMPARATOR
Intervention: CMF-treated patients
Number of subjects: 1000
Study 11134193 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast irradiation
Number of subjects: 1000
Study 9062529 — intervention group
Group type: COMPARATOR
Intervention: Mixed diet containing 100 micrograms phylloquinone/d
Number of subjects: 9
Study 9062529 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemented diet with 420 micrograms phylloquinone/d on days 6 through 10
Number of subjects: 9
Study 9062529 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemented diet with 420 micrograms phylloquinone/d
Number of subjects: 9
Study 9062529 — intervention group
Group type: COMPARATOR
Intervention: Mixed diet after supplementation
Number of subjects: 9
Study 9062529 — intervention group
Group type: COMPARATOR
Intervention: Mixed diet
Number of subjects: 9
Study 7956752 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone treatment
Number of subjects: 0
Study 7956752 — intervention group
Group type: EXPERIMENTAL
Intervention: Resumption of treatment during follow-up
Number of subjects: 0
Study 2837046 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin 1% ophthalmic solution (one drop the evening before surgery and one drop 45 minutes before surgery)
Number of subjects: 27
Study 2837046 — intervention group
Group type: COMPARATOR
Intervention: Standard preoperative dilation regime (no indomethacin)
Number of subjects: 27
Study 29186984 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy eating intervention
Number of subjects: 151
Study 29186984 — intervention group
Group type: COMPARATOR
Intervention: Control group (delayed intervention)
Number of subjects: 151
Study 27733560 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled CVT‐301 (50 mg)
Number of subjects: 24
Study 27733560 — intervention group
Group type: COMPARATOR
Intervention: Oral carbidopa/levodopa (25 mg/100 mg)
Number of subjects: 24
Study 23347336 — intervention group
Group type: COMPARATOR
Intervention: Preoperatively 2 g of amoxycillin 1 h before surgery (positive control, PC)
Number of subjects: 329
Study 23347336 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperatively 2 g of amoxycillin immediately following surgery (test 1, T1)
Number of subjects: 329
Study 23347336 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperatively 2 g of amoxycillin 1 h before and 500 mg thrice daily on days 2 and 3 after surgery (test 2, T2)
Number of subjects: 329
Study 23347336 — intervention group
Group type: COMPARATOR
Intervention: Preoperatively 2 g of placebo 1 h before surgery (negative control, NC)
Number of subjects: 329
Study 23386557 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided self-help interventions
Number of subjects: 0
Study 21458404 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure plus Safety Behaviour (E + SB)
Number of subjects: 80
Study 21458404 — intervention group
Group type: COMPARATOR
Intervention: Exposure and Response Prevention (ERP)
Number of subjects: 80
Study 18299694 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate
Number of subjects: 0
Study 18299694 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium and plain vitamin D3 supplementation
Number of subjects: 0
Study 18299694 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisphosphonates
Number of subjects: 0
Study 18299694 — intervention group
Group type: EXPERIMENTAL
Intervention: General measurements (low dose and short period of glucocorticoids)
Number of subjects: 0
Study 16805710 — intervention group
Group type: EXPERIMENTAL
Intervention: Platinum-based adjuvant therapy in patients with resected stage IB and II NSCLC
Number of subjects: 0
Study 16805710 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant chemotherapy in resected stage III NSCLC
Number of subjects: 0
Study 16805710 — intervention group
Group type: COMPARATOR
Intervention: Targeted agents
Number of subjects: 0
Study 16805710 — intervention group
Group type: COMPARATOR
Intervention: Gene expression profiling studies
Number of subjects: 0
Study 12788409 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated limb perfusion with melphalan
Number of subjects: 1038
Study 12788409 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic isolated limb perfusion
Number of subjects: 1038
Study 11061252 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan
Number of subjects: 19
Study 11061252 — intervention group
Group type: COMPARATOR
Intervention: Active placebo (low-dose lorazepam)
Number of subjects: 19
Study 9366102 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril 4 mg
Number of subjects: 128
Study 9366102 — intervention group
Group type: COMPARATOR
Intervention: Trandolapril 2 mg
Number of subjects: 128
Study 8398512 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse oximetry monitoring (group I)
Number of subjects: 736
Study 8398512 — intervention group
Group type: COMPARATOR
Intervention: No pulse oximetry monitoring (group II)
Number of subjects: 736
Study 8398512 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up study for patients with WMS scores 10 points less after surgery
Number of subjects: 736
Study 3615347 — intervention group
Group type: EXPERIMENTAL
Intervention: Clovoxamine 50 mg, 100 mg, 150 mg
Number of subjects: 12
Study 3615347 — intervention group
Group type: EXPERIMENTAL
Intervention: Mianserin 20 mg
Number of subjects: 12
Study 3615347 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 3615347 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol 0.8 g/kg
Number of subjects: 12
Study 29381651 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute exercise (EX)
Number of subjects: 65
Study 29381651 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 65
Study 29381651 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (16 weeks)
Number of subjects: 65
Study 26724489 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT-D
Number of subjects: 1197
Study 26724489 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated baseline BNP (> median = 72 ng/L)
Number of subjects: 1197
Study 26724489 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-year BNP levels
Number of subjects: 1197
Study 26724489 — intervention group
Group type: COMPARATOR
Intervention: ICD only
Number of subjects: 1197
Study 25319676 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinnitus Retraining Therapy (TRT)
Number of subjects: 0
Study 25319676 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial TRT
Number of subjects: 0
Study 25319676 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study 25319676 — intervention group
Group type: EXPERIMENTAL
Intervention: TRT counseling and sound therapy
Number of subjects: 0
Study 25319676 — intervention group
Group type: EXPERIMENTAL
Intervention: Audiological outcomes
Number of subjects: 0
Study 25319676 — intervention group
Group type: EXPERIMENTAL
Intervention: Beck Depression Inventory Fast Screen
Number of subjects: 0
Study 15358440 — intervention group
Group type: COMPARATOR
Intervention: Recombinant human GH (rhGH, Somatropin) replacement therapy for 6 months (Group I)
Number of subjects: 18
Study 15358440 — intervention group
Group type: EXPERIMENTAL
Intervention: Open study design with GH treatment for 6 months (Group II)
Number of subjects: 18
Study 12795775 — intervention group
Group type: EXPERIMENTAL
Intervention: Permethrin-impregnated uniforms
Number of subjects: 272
Study 12795775 — intervention group
Group type: COMPARATOR
Intervention: Control uniforms (washed in water)
Number of subjects: 272
Study 9582849 — intervention group
Group type: EXPERIMENTAL
Intervention: Education about diabetes and frequent periodical checkups
Number of subjects: 13
Study 9582849 — intervention group
Group type: COMPARATOR
Intervention: Conventional insulin therapy (two daily injections of a mixture of regular insulin/NPH)
Number of subjects: 13
Study 7609279 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (0.15 mg of Somatropin per kilogram per day)
Number of subjects: 20
Study 7609279 — intervention group
Group type: COMPARATOR
Intervention: Vehicle of infusion (Control)
Number of subjects: 20
Study 1977781 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine, 10 mg
Number of subjects: 0
Study 1977781 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine, 120 mg
Number of subjects: 0
Study 1977781 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine, 60 mg
Number of subjects: 0
Study 1977781 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine, 10 mg
Number of subjects: 0
Study 1977781 — intervention group
Group type: EXPERIMENTAL
Intervention: Astemizole, 10 mg
Number of subjects: 0
Study 1977781 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpheniramine, 4 mg
Number of subjects: 0
Study 1977781 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 416322 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofibate (1 g b.i.d.)
Number of subjects: 0
Study 416322 — intervention group
Group type: COMPARATOR
Intervention: Lactose placebo (1 g b.i.d.)
Number of subjects: 0
Study 31537316 — intervention group
Group type: EXPERIMENTAL
Intervention: My Birth Control decision support tool
Number of subjects: 70
Study 31537316 — intervention group
Group type: COMPARATOR
Intervention: Standard counseling without the tool
Number of subjects: 70
Study 30567286 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatty fish consumption (2nd quintile)
Number of subjects: 6587
Study 30567286 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatty fish consumption (3rd quintile)
Number of subjects: 6587
Study 30567286 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatty fish consumption (4th quintile)
Number of subjects: 6587
Study 30567286 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate intake of total LC ω‐3 PUFA (approximately 0.5⁻1 g/day)
Number of subjects: 6587
Study 30567286 — intervention group
Group type: EXPERIMENTAL
Intervention: Total seafood consumption
Number of subjects: 6587
Study 27708129 — intervention group
Group type: EXPERIMENTAL
Intervention: M1 rTMS
Number of subjects: 50
Study 27708129 — intervention group
Group type: COMPARATOR
Intervention: DLPFC rTMS
Number of subjects: 50
Study 27708129 — intervention group
Group type: COMPARATOR
Intervention: M1 + DLPFC rTMS
Number of subjects: 50
Study 27708129 — intervention group
Group type: COMPARATOR
Intervention: Double sham
Number of subjects: 50
Study 24419108 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiotherapy (CRT) plus surgery
Number of subjects: 422
Study 24419108 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 422
Study 20298509 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Number of subjects: 367
Study 20298509 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine inhaler
Number of subjects: 367
Study 20298509 — intervention group
Group type: COMPARATOR
Intervention: Control (before enrolment)
Number of subjects: 367
Study 20298509 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 367
Study 20537722 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual Assisted Cognitive Therapy (MACT)
Number of subjects: 16
Study 20537722 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual Assisted Cognitive Therapy (MACT) + Therapeutic Assessment (TA)
Number of subjects: 16
Study 20537722 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 16
Study 18165083 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac tromethamine 0.5%
Number of subjects: 98
Study 15748130 — intervention group
Group type: EXPERIMENTAL
Intervention: Consultation with a nurse for 45 minutes, including a tutorial discussion on normal sleep patterns and written material.
Number of subjects: 268
Study 15748130 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 268
Study 15748130 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control).
Number of subjects: 268
Study 11872281 — intervention group
Group type: EXPERIMENTAL
Intervention: Institutions that enrolled >= 5 patients
Number of subjects: 239
Study 11872281 — intervention group
Group type: COMPARATOR
Intervention: Institutions that enrolled < 5 patients
Number of subjects: 239
Study 10028217 — intervention group
Group type: EXPERIMENTAL
Intervention: SBT with social support strategies
Number of subjects: 166
Study 10028217 — intervention group
Group type: COMPARATOR
Intervention: Standard Behavioral Treatment (SBT)
Number of subjects: 166
Study 7552878 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine rinse (5 ml, 500 mg)
Number of subjects: 14
Study 7552878 — intervention group
Group type: COMPARATOR
Intervention: Placebo rinse (5 ml)
Number of subjects: 14
Study 2147909 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin (mean dose 11 mg) + Atenolol (100 mg)
Number of subjects: 87
Study 2147909 — intervention group
Group type: COMPARATOR
Intervention: Atenolol (100 mg) + Placebo
Number of subjects: 87
Study 7017122 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole and active neomycin
Number of subjects: 73
Study 7017122 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole and placebo neomycin
Number of subjects: 73
Study 31152762 — intervention group
Group type: EXPERIMENTAL
Intervention: Prominent calorie labelling for all cafeteria products (displayed in bold capitalised Verdana typeface with a minimum font size of 14)
Number of subjects: 3
Study 31152762 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-intervention feedback from patrons
Number of subjects: 3
Study 28183547 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine with sufentanil
Number of subjects: 60
Study 28183547 — intervention group
Group type: COMPARATOR
Intervention: Sufentanil infusion
Number of subjects: 60
Study 26099195 — intervention group
Group type: EXPERIMENTAL
Intervention: Zn alone group (30 mg ZnSO4 daily)
Number of subjects: 675
Study 26099195 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined group (30 mg ZnSO4 plus multivitamins)
Number of subjects: 675
Study 26099195 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo, 270 mg lactose)
Number of subjects: 675
Study 26099195 — intervention group
Group type: EXPERIMENTAL
Intervention: Zn alone group
Number of subjects: 675
Study 26099195 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined group
Number of subjects: 675
Study 23998397 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 356
Study 23998397 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 356
Study 21410693 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirror therapy (15 minutes of daily bimanual training with a mirror for 3 weeks)
Number of subjects: 10
Study 21410693 — intervention group
Group type: COMPARATOR
Intervention: Bimanual training without a mirror (15 minutes daily for 3 weeks)
Number of subjects: 10
Study 21410693 — intervention group
Group type: EXPERIMENTAL
Intervention: Grasp strength testing behind the mirror
Number of subjects: 10
Study 19281729 — intervention group
Group type: EXPERIMENTAL
Intervention: New oral topotecan formulation (4 mg dose)
Number of subjects: 108
Study 19281729 — intervention group
Group type: COMPARATOR
Intervention: Current oral topotecan formulation (4 mg dose)
Number of subjects: 108
Study 19281729 — intervention group
Group type: EXPERIMENTAL
Intervention: New oral topotecan formulation (4 mg dose) in fed state
Number of subjects: 108
Study 19281729 — intervention group
Group type: EXPERIMENTAL
Intervention: New oral topotecan formulation (4 mg dose) in fasted state
Number of subjects: 108
Study 19281729 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety data for all subjects (n = 108)
Number of subjects: 108
Study 17587424 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide 100 microg
Number of subjects: 311
Study 17587424 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide 200 microg
Number of subjects: 311
Study 17587424 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide 400 microg
Number of subjects: 311
Study 17587424 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 311
Study 15547701 — intervention group
Group type: EXPERIMENTAL
Intervention: oral doxifluridine
Number of subjects: 12
Study 15547701 — intervention group
Group type: COMPARATOR
Intervention: intravenous infusion of 5-FU
Number of subjects: 12
Study 15547701 — intervention group
Group type: EXPERIMENTAL
Intervention: intravenous infusion of irinotecan
Number of subjects: 12
Study 15547701 — intervention group
Group type: EXPERIMENTAL
Intervention: combination of doxifluridine and irinotecan
Number of subjects: 12
Study 11573674 — intervention group
Group type: EXPERIMENTAL
Intervention: StyletScope
Number of subjects: 0
Study 11573674 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 0
Study 9817589 — intervention group
Group type: EXPERIMENTAL
Intervention: Overshadowing+ (OV+)
Number of subjects: 16
Study 9817589 — intervention group
Group type: COMPARATOR
Intervention: Overshadowing- (OV-)
Number of subjects: 16
Study 8067215 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.4 mmHg (1 kPa) continuous positive airway pressure (CPAP)
Number of subjects: 30
Study 8067215 — intervention group
Group type: COMPARATOR
Intervention: 30% oxygen by mask with ambient airway pressure (Control)
Number of subjects: 30
Study 8067215 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 30
Study 8067215 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP
Number of subjects: 30
Study 2845349 — intervention group
Group type: EXPERIMENTAL
Intervention: RRV vaccine (10^4 plaque-forming units)
Number of subjects: 176
Study 2845349 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 176
Study 31675124 — intervention group
Group type: EXPERIMENTAL
Intervention: M2000
Number of subjects: 12
Study 29382467 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma Rich in Growth Factors (PRGF)
Number of subjects: 38
Study 29382467 — intervention group
Group type: COMPARATOR
Intervention: Alvogyl (positive control)
Number of subjects: 38
Study 28760801 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual antibiotic treatment with the addition of 8 L of polyethylene glycol (PEG) lavage via nasojejunal tube
Number of subjects: 24
Study 28760801 — intervention group
Group type: COMPARATOR
Intervention: Usual antibiotic treatment
Number of subjects: 24
Study 26580743 — intervention group
Group type: EXPERIMENTAL
Intervention: γ-tACS
Number of subjects: 18
Study 26580743 — intervention group
Group type: COMPARATOR
Intervention: tDCS
Number of subjects: 18
Study 26580743 — intervention group
Group type: COMPARATOR
Intervention: sham tDCS
Number of subjects: 18
Study 23200785 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial laser stimulation (n=20)
Number of subjects: 40
Study 23200785 — intervention group
Group type: COMPARATOR
Intervention: Placebo control (n=20)
Number of subjects: 40
Study 21515916 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab plus methotrexate
Number of subjects: 104
Study 21515916 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab re-introduction after cessation
Number of subjects: 104
Study 21515916 — intervention group
Group type: COMPARATOR
Intervention: Joint damage progression rate
Number of subjects: 104
Study 21515916 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictors for re-introduction of infliximab
Number of subjects: 104
Study 21515916 — intervention group
Group type: COMPARATOR
Intervention: Non-smoking, SE-negative patients treated <18 months
Number of subjects: 104
Study 19081881 — intervention group
Group type: EXPERIMENTAL
Intervention: Elliptical component without holes and sintered beads
Number of subjects: 0
Study 19081881 — intervention group
Group type: COMPARATOR
Intervention: Hemispherical components with more holes
Number of subjects: 0
Study 19081881 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma-spray and small-bead coatings
Number of subjects: 0
Study 17157114 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan injection 6 mg
Number of subjects: 784
Study 17157114 — intervention group
Group type: COMPARATOR
Intervention: Control (inactive vehicle)
Number of subjects: 784